Thiamine (Vitamin B1): Benefits, Uses, and Sources

1. Drug Interactions

Thiamine itself does not significantly inhibit or induce hepatic cytochrome P450 enzymes and is not a substrate, inducer, or inhibitor of clinically significant drug-metabolizing transporters. Drug interactions therefore proceed unidirectionally — drugs affect thiamine status rather than vice versa.

Nutrient interactions of clinical relevance:

• Magnesium (essential co-cofactor) — required for all TDP-dependent enzyme activities; hypomagnesemia produces functional thiamine deficiency despite adequate thiamine. ALWAYS check and correct Mg when treating thiamine deficiency
• Riboflavin (B2) — required for FAD-dependent E3 component of α-keto acid dehydrogenase complexes; concurrent deficiency compounds clinical picture
• Niacin (B3) — required for NAD-dependent E3 component of α-keto acid dehydrogenase complexes; same rationale
• Folate, B12 — independent metabolism but share macrocytic anemia presentation in TRMA where deafness and diabetes are additional diagnostic clues

2. Contraindications

Thiamine has an extraordinarily favorable contraindication profile. Absolute contraindications are limited; most clinical decision-making centers on precautions and risk-benefit considerations rather than outright contraindications. The detailed cautions are organized in the nested Block F sub-sections below.

The four nested Block F sub-sections below cover specific clinical caution scenarios in detail.

2a. Patient Population Red Flags

Specific populations require heightened caution OR mandate supplementation rather than restriction:

2b. Parenteral Administration Cautions

IV thiamine has a small but well-documented anaphylactoid risk. Historical case-fatality estimates from undiluted rapid IV push are higher than modern administration practice produces. Mechanism is thought to be IgE-mediated in sensitized individuals (true anaphylaxis) and non-IgE mast-cell degranulation in others (anaphylactoid), with the thiazolium ring as the likely antigenic determinant [11]Morinville IV thiamine anaphylaxis. Open Source ↗.

Best-practice administration parameters:

• Preferred route: dilute in 50–100 mL NS or D5W and infuse over 30 minutes (does not reduce CNS penetration relative to push)
• Maximum IV push rate (when push is necessary): 100 mg over 1 minute
• Resuscitation equipment immediately available during the first dose for any patient
• IM administration is acceptable but painful and produces erratic kinetics; reserve for patients without IV access
• Document indication, dose, route, and any reaction

2c. Lipophilic Derivative Cautions

Lipophilic thiamine derivatives — benfotiamine, sulbutiamine, fursultiamine (TTFD), allithiamine — bypass the saturable active-transport ceiling (SLC19A2/A3, ~5 mg per oral dose) that limits oral water-soluble thiamine absorption. They achieve plasma Cmax ~5× and AUC up to ~3.6× higher than equimolar oral thiamine HCl [14]Loew 1996 benfotiamine PK. Open Source ↗ [15]Xie 2014 benfotiamine vs HCl PK. Open Source ↗.

Clinical implications of this enhanced bioavailability:

• The UK EVM 100 mg/d advisory guidance level applies EXCLUSIVELY to water-soluble forms (HCl, mononitrate); it does NOT apply to benfotiamine or other lipophilic derivatives [16]UK COT/EVM Thiamine guidance. Open Source ↗
• Clinical-trial doses for benfotiamine range 300–600 mg/d (BEDIP, BENDIP, BOND trials [17]BEDIP 2005 benfotiamine RCT. Open Source ↗ [18]BENDIP 2008 benfotiamine phase III. Open Source ↗ [19]BOND 2022 protocol BMJ Open. Open Source ↗); these doses are pharmacologic, not nutritional
• Long-term high-dose lipophilic-derivative safety in special populations (pregnancy, lactation, hepatic/renal impairment) is less well-characterized than water-soluble thiamine — patient education and clinician oversight appropriate
• Lipophilic derivatives are NOT bioequivalent to water-soluble thiamine for routine supplementation; selecting between forms requires the clinician to think about the indication (general supplementation → HCl; investigational DPN trials → benfotiamine)

2d. Critical Sequencing — Thiamine Before Glucose

The single most important sequencing rule in thiamine pharmacology: in any patient at risk for thiamine deficiency, administer parenteral thiamine BEFORE or concurrently with IV dextrose, never after.

Pathophysiologic rationale: in a thiamine-deficient patient, the body's residual TDP pool is being conserved by reduced metabolic flux. Acute glucose loading (IV dextrose, refeeding, oral carbohydrate bolus) demands rapid increase in PDH and α-KGDH activity, which consume the remaining TDP. This precipitates or worsens the neurochemistry underlying Wernicke's encephalopathy: selective vulnerability of periaqueductal gray, medial thalami, and mammillary bodies with focal lactate accumulation and BBB disruption [20]Wernicke's diagnostic challenge review. Open Source ↗.

Operational rules:

• Any patient with possible AUD, severe malnutrition, hyperemesis, prolonged poor PO intake, post-bariatric, or HIV/AIDS cachexia receiving IV dextrose → 100 mg IV thiamine first or concurrently
• ED triage: order thiamine 100 mg IV BEFORE dextrose for any altered-mental-status patient with unclear etiology where deficiency cannot be excluded
• TPN initiation: verify thiamine is included in the IV multivitamin order (FDA-mandated minimum 6 mg/d adult since 1989); do not initiate TPN without thiamine
• Refeeding syndrome: thiamine 200–300 mg IV daily × 3 days BEFORE refeeding initiation in any patient with BMI <16, weight loss >15% in 3–6 months, or minimal intake >10 days. Continue 100 mg/d × first 10 days of refeeding with concomitant phosphate, potassium, and magnesium monitoring
• Document the rationale and sequence in the medical record

Concurrent magnesium repletion is essential — TDP-dependent enzymes additionally require Mg²⁺ as a co-cofactor, and hypomagnesemia produces functional thiamine deficiency even with adequate thiamine levels. The bedside rule: treat thiamine, treat magnesium.

3. Therapeutic Dosing

FDA-approved indications and labeled dosing (parenteral thiamine HCl, per DailyMed labeling [21]DailyMed Thiamine HCl Injection. Open Source ↗):

Off-label and supportive-care dosing (clinical practice, not FDA-approved indications):

Administration pearls:

• Dilute parenteral thiamine in 50–100 mL NS or D5W; infuse over 30 minutes (see Block F.2b)
• Always check and correct hypomagnesemia simultaneously — Mg is the essential co-cofactor
• In Wernicke's, treat empirically without delay; the diagnosis is clinical per Caine criteria [26]Caine 1997 operational criteria. Open Source ↗; do not wait for biomarker confirmation
• Recognize 'thiamine before glucose' as a safety RULE, not a sequencing preference
• Document indication, route, dose, and any reaction
• Discharge teaching for outpatient maintenance must address ongoing risk factors (alcohol use, malnutrition, etc.) not just the prescription

4. Clinical Evidence

The four-tier framework summarizes the published evidence base. Tier A reflects FDA-approved or near-universally-accepted use; tier B reflects strong evidence in specific populations; tier C reflects active research with mixed pooled results; tier D reflects exploratory or hypothesis-generating research.

Tier A — Established / FDA-approved [8]StatPearls — Vitamin B1. Open Source ↗:

• Wernicke's encephalopathy: empiric treatment is standard of care; Caine 1997 operational criteria [26]Caine 1997 operational criteria. Open Source ↗ and EFNS 2010 [6]EFNS 2010 Wernicke guidelines. Open Source ↗ anchor diagnosis and treatment; Cochrane 2013 [7]Cochrane 2013 Wernicke-Korsakoff thiamine. Open Source ↗ acknowledged insufficient RCT evidence to specify dose/frequency but did NOT undermine established empiric high-dose parenteral practice; Dingwall 2022 RCT [27]Dingwall 2022 thiamine dose RCT. Open Source ↗ tested low vs intermediate vs high dose and found no benefit of very high doses
• Infantile beriberi: lifesaving in acute presentation
• Wet beriberi (cardiac): rapid improvement with empiric parenteral therapy
• Documented thiamine deficiency (any cause): repletion is the indication
• Pre-glucose prophylaxis in marginal-status patients: 100 mg IV before any IV dextrose
• TPN co-administration: standard of care; FDA-mandated minimum 6 mg/d adult since 1989 outbreak of lactic-acidosis deaths in thiamine-omitted TPN

Tier B — Strong evidence in specific populations [22]Gomes 2021 non-alcoholic thiamine deficiency. Open Source ↗ [9]Thiamine in DM/obesity/bariatric. Open Source ↗:

• AUD Wernicke's prophylaxis: Dingwall 2022 RCT [27]Dingwall 2022 thiamine dose RCT. Open Source ↗ found no benefit of high vs intermediate vs low dose but did not test against placebo; clinical consensus remains parenteral supplementation in active withdrawal
• Post-bariatric supplementation: bariatric MVI with thiamine ≥12 mg/d per ASMBS guidance; 'bariatric beriberi' documented in surveillance registries when non-adherent [9]Thiamine in DM/obesity/bariatric. Open Source ↗
• Refeeding syndrome prophylaxis: 200–300 mg IV before refeeding initiation in nutritional rehabilitation protocols
• Genetic thiamine-responsive disorders (TRMA via SLC19A2, BTBGD via SLC19A3, thiamine-responsive MSUD, TPK1 deficiency): lifelong pharmacologic dosing is the treatment [10]Marcé-Grau — thiamine genetics review. Open Source ↗ [23]GeneReviews — TRMA. Open Source ↗

Tier C — Mixed pooled results, active research:

Tier D — Exploratory / hypothesis-generating:

• Alzheimer's disease and cognitive decline: benfotiamine pilot studies suggest biomarker-level effects (reduced AGE accumulation); no clinical efficacy demonstrated
• Diabetic microvascular complications (retinopathy, nephropathy): Hammes 2003 [28]Hammes 2003 Nat Med benfotiamine. Open Source ↗ mechanism underpins ongoing research; no definitive trials
• Chemotherapy-induced peripheral neuropathy (CIPN): biochemical rationale via transketolase activation; early-phase trials only
• Mood disorders and depression: limited and inconsistent evidence
• Athletic performance and endurance: no evidence beyond correction of frank deficiency

5. Adverse Effects

Tolerable Upper Intake Level: NOT established by IOM/NAM [32]NAM DRI — Thiamin. Open Source ↗, EFSA [33]EFSA DRV Thiamin (2016). Open Source ↗, or UK EVM [16]UK COT/EVM Thiamine guidance. Open Source ↗. The UK EVM issued an advisory guidance level of 100 mg/d for water-soluble thiamine forms based on absence of adverse effects in a 60–90-day clinical trial of 556 young women at that dose. The Nordic Nutrition Recommendations 2023 likewise did not set a UL.

Symptoms reported only at very high oral doses (≥7,000 mg/d thiamine HCl per UK EVM source documentation [16]UK COT/EVM Thiamine guidance. Open Source ↗): headache, nausea, irritability, insomnia, rapid pulse, and weakness. These doses are far above any conventional supplementation. No fatal overdose from oral thiamine has been documented in the published literature.

MedDRA-categorized adverse events with oral thiamine:

Parenteral thiamine adverse effects (quantitative summary; full administration safety detail in Block F.2b above):

Pediatric safety: FDA-approved injectable thiamine indicated in infantile beriberi at weight-based dosing (10–25 mg IM or slow IV BID-QID). Oral thiamine within DRI is well tolerated across all pediatric age groups.

Pregnancy and lactation safety: Thiamine is essential during both. The 1.4 mg/d RDA reflects increased demand. No teratogenic signal has emerged across decades of standard prenatal multivitamin use. In hyperemesis gravidarum, parenteral thiamine 100 mg IV is given before any IV dextrose to prevent gestational Wernicke's encephalopathy; case literature supports both efficacy and safety in this indication [8]StatPearls — Vitamin B1. Open Source ↗ [22]Gomes 2021 non-alcoholic thiamine deficiency. Open Source ↗.

Geriatric safety: No dose-adjustment for age. Older adults may have higher baseline prevalence of marginal status — supplementation if anything more appropriate rather than less.

Hepatic and renal impairment: No dose-adjustment for hepatic impairment (no hepatic biotransformation required for activity). Renal impairment without dialysis does not warrant adjustment. Dialysis substantially clears thiamine — empiric 100 mg/d oral supplementation in chronic intermittent hemodialysis is common expert practice [22]Gomes 2021 non-alcoholic thiamine deficiency. Open Source ↗.

6. Mechanism of Action

Following absorption, thiamine is phosphorylated by thiamine pyrophosphokinase 1 (TPK1) in the cytosol to thiamine diphosphate (TDP, also called thiamine pyrophosphate, TPP) — the active cofactor form [34]Hrubša thiamin & energy metabolism. Open Source ↗. A small fraction is further phosphorylated to thiamine triphosphate (TTP) and the recently characterized adenosine thiamine triphosphate (AThTP) and adenosine thiamine diphosphate (AThDP); these phosphorylated derivatives have putative roles in nerve membrane signalling that remain under investigation.

TDP serves as a cofactor for five distinct mammalian enzyme activities, all requiring Mg²⁺ as a co-cofactor at the active site [34]Hrubša thiamin & energy metabolism. Open Source ↗ [35]Ciszak PDH structural mechanism. Open Source ↗:

Detailed enzymology. TDP-dependent enzymes catalyze reactions involving cleavage of bonds adjacent to a carbonyl (the 'Breslow mechanism' of thiamine catalysis). The C2 carbon of the thiazolium ring is acidic (pKa ~18 in solution, lowered to ~12 at enzyme active sites by V-shaped Mg²⁺ coordination), allowing deprotonation to a carbene-like ylide that nucleophilically attacks the substrate carbonyl [35]Ciszak PDH structural mechanism. Open Source ↗.

Each of the three α-keto acid dehydrogenase complexes (PDH, α-KGDH, BCKDH) is a large multi-enzyme complex (>4 MDa) containing three catalytic components: E1 TDP-binding decarboxylase, E2 dihydrolipoyl acyltransferase, E3 dihydrolipoyl dehydrogenase, plus regulatory kinases and phosphatases. Ciszak et al. (2003) crystallized the human PDH E1 component and demonstrated the 'flip-flop' active-site mechanism in which the two α subunits of the heterotetramer alternate catalytic cycles synchronously, coordinated through long-range conformational changes [35]Ciszak PDH structural mechanism. Open Source ↗.

Transketolase (TKT) is a smaller cytosolic homodimer (~140 kDa) that catalyzes the reversible transfer of a 2-carbon ketol unit between sugar phosphates. It is the linchpin of the non-oxidative arm of the pentose phosphate pathway, interchanging ribose-5-phosphate, xylulose-5-phosphate, sedoheptulose-7-phosphate, fructose-6-phosphate, and glyceraldehyde-3-phosphate. Erythrocyte transketolase activity coefficient (ETKAC) measurement exploits this enzyme directly to assess thiamine status (see §12) [37]Krebs ETKAC protocol. Open Source ↗.

HACL1, the recently characterized 5th mammalian TPP-dependent enzyme, was long missed because it is peroxisomal and operates on α-oxidation substrates rather than the better-known TCA/glycolytic intermediates. Fraccascia et al. first demonstrated TDP requirement and presence in mammalian peroxisomes; this clarified why phytanic acid catabolism (which proceeds via α-oxidation) is partially thiamine-dependent [36]Fraccascia TPP peroxisomes. Open Source ↗.

Why high-flux tissues are most affected by deficiency: neuronal tissue is almost wholly dependent on glucose oxidation for ATP production, and cardiac myocytes are similarly oxidative. When PDH and α-KGDH flux falls due to inadequate TDP, these tissues cannot adequately substitute alternative substrates rapidly. Skeletal muscle is more metabolically flexible and is comparatively spared in early deficiency. This explains the selective vulnerability of periaqueductal gray, medial thalami, mammillary bodies (Wernicke's encephalopathy distribution) and myocardium (wet beriberi).

7. Pharmacokinetics (ADME)

Absorption. Intestinal uptake of thiamine occurs primarily in the proximal jejunum via two high-affinity carrier proteins:

• SLC19A2 (ThTR-1, thiamine transporter 1) — basolateral; high affinity (Km ~25 nM); tissue distribution includes bone marrow, ear, and pancreatic β-cell; loss-of-function mutations cause TRMA (Rogers syndrome) [38]Zhao 2013 SLC19A1-3. Open Source ↗ [23]GeneReviews — TRMA. Open Source ↗
• SLC19A3 (ThTR-2, thiamine transporter 2) — apical; high affinity (Km ~25 nM); high expression at intestinal epithelium and blood-brain barrier; loss-of-function mutations cause biotin-thiamine-responsive basal ganglia disease (BTBGD) [38]Zhao 2013 SLC19A1-3. Open Source ↗
• Passive diffusion — operative at higher pharmacologic concentrations (oral doses above ~5 mg saturate carrier-mediated transport)

Oral bioavailability of thiamine HCl is 3.7–5.3% — the lowest among the B-vitamins — constrained by the saturable carrier system [21]DailyMed Thiamine HCl Injection. Open Source ↗. Above ~5 mg/dose, the increment in absorption from active transport plateaus and passive diffusion takes over, providing lower fractional bioavailability at higher doses [15]Xie 2014 benfotiamine vs HCl PK. Open Source ↗.

Benfotiamine bypasses the SLC19A transporter system. Its lipophilic S-benzoyl group is hydrolyzed by intestinal ENPP3 (ectonucleotide pyrophosphatase/phosphodiesterase 3) to S-benzoyl thiamine, which crosses the brush border by passive diffusion. Xie et al. (2014) compared 200 mg benfotiamine vs 200 mg thiamine HCl in healthy volunteers and reported plasma Cmax ~5× higher and AUC ~3.6× higher for the benfotiamine form [15]Xie 2014 benfotiamine vs HCl PK. Open Source ↗. Erythrocyte TDP after sustained dosing is approximately 2× higher with benfotiamine. The UK EVM 100 mg/d guidance for water-soluble forms explicitly does NOT apply to benfotiamine [16]UK COT/EVM Thiamine guidance. Open Source ↗.

Distribution. Total body pool is approximately 25–30 mg, of which ~80% exists as TDP, ~10% as TTP, and the remainder as free thiamine and TMP [39]NIH ODS Thiamin (HP). Open Source ↗. Skeletal muscle holds the largest reservoir (~50% of total body thiamine) by mass, followed by liver, heart, brain, and kidney. Plasma free thiamine half-life is 1–12 hours; this short half-life reflects rapid cellular uptake and renal clearance of unphosphorylated thiamine. Functional reserves are depleted in 2–3 weeks of zero intake (notably shorter than other B-vitamins) [39]NIH ODS Thiamin (HP). Open Source ↗ [8]StatPearls — Vitamin B1. Open Source ↗.

Blood-brain barrier transport: SLC19A3 is the principal BBB-resident thiamine transporter. This explains the severe childhood encephalopathy of BTBGD (SLC19A3 loss-of-function) and the targeted CNS effect of clinical thiamine deficiency in mammillary bodies and periaqueductal gray.

Metabolism. Intracellular thiamine pyrophosphokinase 1 (TPK1) catalyzes the rate-limiting conversion of free thiamine to TDP using ATP. TPK1 deficiency (autosomal recessive) presents as episodic encephalopathy responsive to high-dose thiamine. Beyond TDP, smaller fractions are further phosphorylated to TTP and the adenosylated forms AThDP/AThTP with putative non-cofactor functions [34]Hrubša thiamin & energy metabolism. Open Source ↗.

Excretion. Renal. Unphosphorylated thiamine is filtered freely at the glomerulus, partially reabsorbed in the proximal tubule, and excreted at rates proportional to plasma concentration and renal handling. 24-hour urinary thiamine excretion is the most commonly used dietary-adequacy marker (<100 mcg/d insufficient; <40 mcg/d severely inadequate). Hemodialysis removes substantial thiamine — clinically relevant losses in patients on chronic intermittent hemodialysis [22]Gomes 2021 non-alcoholic thiamine deficiency. Open Source ↗ [9]Thiamine in DM/obesity/bariatric. Open Source ↗.

8. Pharmacogenomics & Genetics

Thiamine pharmacology has six well-characterized monogenic disorders, three of which respond dramatically to high-dose thiamine supplementation. Unlike most pharmacogenomic loci, these are not common-variant pharmacogenes but rare loss-of-function variants that change the entire clinical phenotype. Recognition of these conditions is high-yield because the treatment is straightforward (oral thiamine, sometimes with biotin) and often lifelong [10]Marcé-Grau — thiamine genetics review. Open Source ↗ [23]GeneReviews — TRMA. Open Source ↗.

Common-variant pharmacogenomics. Common SLC19A2 and SLC19A3 polymorphisms have been identified, but to date NO common variant has been clinically validated as requiring different thiamine dosing in the general population. Research in T2DM and gout populations has examined whether common SLC19A3 haplotypes affect thiamine status or disease susceptibility, but findings are preliminary [38]Zhao 2013 SLC19A1-3. Open Source ↗ [10]Marcé-Grau — thiamine genetics review. Open Source ↗.

Practical diagnostic pearls:

• Any childhood encephalopathy of unclear etiology with bilateral basal ganglia involvement on MRI: consider BTBGD; start empiric biotin + thiamine while awaiting genetic confirmation. The diagnostic stakes are high — untreated BTBGD causes permanent neurologic damage
• Childhood megaloblastic anemia not explained by B12/folate, especially with deafness or diabetes: consider TRMA; thiamine trial is reasonable before extensive workup
• Childhood maple-syrup urine disease with residual BCKDH activity: distinguish thiamine-responsive subtype because dietary management is less restrictive
• Episodic childhood encephalopathy or ataxia with intercurrent illness triggers: consider TPK1 deficiency
• Whole-exome / whole-genome sequencing is now first-line for atypical pediatric metabolic presentations; recognition of these specific genes in the report changes management

Therapeutic monitoring in genetic disorders: erythrocyte TDP monitoring is useful in TRMA, BTBGD, and TPK1 deficiency to confirm pharmacologic levels are achieved. Clinical response (hematologic in TRMA; neurologic in BTBGD/TPK1) is the primary endpoint. Lifelong specialist follow-up is appropriate.

9. Chemical Identity & Forms

Core chemical identity:

Physicochemical properties:

Pharmaceutical forms — comparative chemistry and pharmacology:

Synthesis. Industrial thiamine synthesis is predominantly via the Williams-Cline route (1936, Merck commercial process [41]Tylicki 2018 — synthesis history. Open Source ↗) or the Grewe-Hill route, both combining a substituted pyrimidine moiety with a substituted thiazole moiety through nucleophilic substitution. The Merck process was historically a challenging 15-step synthesis; modern production is concentrated in a small number of large-scale facilities, primarily in China and a few European producers [41]Tylicki 2018 — synthesis history. Open Source ↗.

Antivitamin analogs (relevant to mechanism and toxicology):

• Amprolium (3-(4-amino-2-propyl-5-pyrimidinylmethyl)-1-(2-picolyl)pyridinium chloride) — veterinary coccidiostat; competes with thiamine for SLC19A transport; causes thiamine deficiency in animals (and rarely humans with high exposure) [41]Tylicki 2018 — synthesis history. Open Source ↗
• Pyrithiamine — thiazole-replaced thiamine analog; research tool for induction of experimental thiamine deficiency
• Oxythiamine — pyrimidine-replaced thiamine analog; research tool
• 3-Deazathiamine — research-stage TPP-mimetic; explored as anti-cancer chemotherapy via transketolase inhibition

10. Organ System Effects

Organ system involvement in thiamine deficiency follows from the mechanism (§6): tissues with high oxidative ATP demand and limited metabolic flexibility are affected first and most severely. The mapping from biochemical lesion to clinical phenotype is one of the cleaner examples in nutrition science.

Brain regional vulnerability — clinical-radiological mapping:

11. Co-Prescribing & Synergy

Rational co-prescribing of thiamine centers on three patterns: (1) essential co-cofactor combinations (magnesium); (2) deficiency-state combinations (B-complex in malabsorption); (3) disease-specific combinations (biotin in BTBGD). Routine general-population supplementation does not require thiamine-specific synergy strategies beyond what a standard multivitamin provides.

Co-prescribing considerations by clinical scenario:

• Alcohol use disorder admission: thiamine 200–500 mg IV TID + Mg (repletion to normal) + B-complex (especially folate and B12 given co-occurring deficiencies) + nutritional support. Glucose only AFTER thiamine, per Block F.2d
• Refeeding syndrome prophylaxis: thiamine 200–300 mg IV daily × 3 days BEFORE refeeding + Mg, phosphate, potassium monitoring/repletion + multivitamin + slow-advance carbohydrate introduction
• Hyperemesis gravidarum: thiamine 100 mg IV before IV dextrose + prenatal MVI when tolerable PO + Mg replacement if low + antiemetic + IV hydration
• Post-bariatric (Roux-en-Y) routine: bariatric MVI with thiamine ≥12 mg/d + iron, B12, calcium, vitamin D per ASMBS guidelines; surveillance erythrocyte TDP annually [9]Thiamine in DM/obesity/bariatric. Open Source ↗
• Chronic dialysis: 100 mg/d oral thiamine + appropriate renal-vitamin formulation (which typically already contains thiamine) + Mg as indicated
• BTBGD: lifelong biotin + thiamine + specialist monitoring (neurology, metabolic genetics)

Drug combinations to AVOID without monitoring:

• Chronic loop diuretic + metformin (multiple thiamine-depleting mechanisms additive): consider proactive thiamine supplementation in T2DM with CHF
• 5-FU chemotherapy + poor nutritional state: empiric thiamine supplementation during cycles
• TPN without confirmed thiamine in the MVI additive: hard rule, do not initiate TPN without thiamine

12. Lab Monitoring + Repletion

Status-assessment hierarchy. Plasma free thiamine alone is uninformative for body status (reflects recent intake only). Erythrocyte TDP measurement by HPLC is the preferred direct intracellular measure. ETKAC (erythrocyte transketolase activity coefficient) is the classic functional indicator. 24-hour urinary thiamine assesses dietary adequacy.

Repletion protocols by clinical scenario:

Practical biomarker decision-making:

• Acute neuropsychiatric presentation suggestive of Wernicke's: DO NOT delay treatment for biomarker results. Empirically treat (see §3) and send labs if available, but the diagnosis remains clinical per Caine criteria [26]Caine 1997 operational criteria. Open Source ↗
• Outpatient screening of high-risk groups (AUD, post-bariatric, dialysis, chronic loop diuretics, T2DM with neuropathy): erythrocyte TDP by HPLC is the best single test if available; ETKAC is acceptable; plasma thiamine alone is uninformative
• Suspected refeeding-syndrome risk: clinical risk stratification (BMI, recent weight loss, intake history) drives management; biomarker confirmation is not required before empiric supplementation
• Population-level epidemiologic studies: 24-hour urinary thiamine is acceptable; erythrocyte TDP is the gold standard
• Test availability varies. Specialty labs (LabCorp, Quest, Mayo Clinic Labs) offer erythrocyte TDP testing; smaller labs may not have it in-house and have to send specimens out — expect 3-7 day turnaround

13. Traditional Medicine

Thiamine deficiency disease has been recognized in clinical medicine — under various culturally-distinct names — for over two millennia. The traditional-medicine history is unusually well-documented and clinically relevant because the traditional dietary remedies (unpolished rice, mixed grains, varied protein) were correct even before the nutritional mechanism was elucidated [46]Lonsdale review — biochemistry & history. Open Source ↗.

Chinese and Japanese medical tradition: jiaoqi / kakke

In classical Chinese medical texts as early as the 1st century, the disease known as jiaoqi (脚气, literally 'foot qi') was described with clinical features that map cleanly onto modern beriberi: distal lower-extremity weakness and numbness progressing proximally, edema, and cardiovascular compromise in late disease. Japanese physicians, following Chinese medical tradition, called the same condition kakke (the phonetic equivalent of jiaoqi) and documented it extensively from the 12th century onward. The Edo-era (1603–1868) Japanese medical literature distinguished the 'dry' form (predominant nerve involvement, emaciation) from the 'wet' form (predominant edema and cardiac involvement) — a distinction that maps directly onto modern dry beriberi vs wet beriberi [46]Lonsdale review — biochemistry & history. Open Source ↗.

Etymology and global spread: the modern term 'beriberi' is believed to come from a Sinhalese (Sri Lankan) phrase meaning 'weak' or 'I cannot, I cannot' — reflecting the profound weakness that characterizes the disease. European physicians colonizing Southeast Asia in the 1600s–1700s adopted this local term for what they observed in port cities and on ships, carrying it into Western medical vocabulary.

The Takaki naval-diet experiments (1880s)

By the 1880s, beriberi was endemic in the Japanese Navy, afflicting 25–40% of sailors with substantial mortality. Kanehiro Takaki, a Japanese naval physician, hypothesized — drawing on both traditional Japanese dietary principles and recent European nutritional thinking — that something in the rice-dominated navy ration was the cause. He arranged a controlled experiment: one ship received the standard polished-rice diet, while a sister ship received a ration of barley, meat, fish, vegetables, and condensed milk. The result: beriberi rates dropped from epidemic levels to nearly zero on the modified diet. Within six years, beriberi was almost completely eliminated in the Japanese Navy. Takaki had identified the correct preventive strategy without knowing the underlying nutrient [46]Lonsdale review — biochemistry & history. Open Source ↗.

Takaki's mechanistic interpretation was incomplete — he believed the issue was protein deficiency rather than thiamine specifically. But his pragmatic dietary change worked, and his work anticipated by 40 years the eventual identification of thiamine as the missing factor. (The Japanese Army, dominated by Western-trained physicians who dismissed Takaki's findings as traditional medicine, persisted with the rice-dominated diet and suffered ~30,000 beriberi cases with ~2,000 deaths during the Sino-Japanese War [46]Lonsdale review — biochemistry & history. Open Source ↗.)

Other traditional sources and their modern reinterpretation:

• Garlic (Allium spp.) — the natural compound allithiamine (a lipophilic form of thiamine) was originally identified from garlic. Traditional medical systems across many cultures have used garlic for general health; the thiamine connection is one biochemical thread in that long ethnobotanical history
• Rice bran — traditional Asian cuisines that retained rice bran (via unpolished or partially polished preparation) provided thiamine intake without modern fortification. The shift to machine-polished white rice in the late 19th century — perceived as superior — coincided with the rise of epidemic beriberi in colonial Asia
• Yeast extract preparations (Marmite, Vegemite, Japanese shoyu/miso fermentation byproducts) — used traditionally as nutritional tonics in several cultures and naturally rich in B-vitamins including thiamine
• Mixed grain porridges and stews — from Korean juk to Japanese okayu to Chinese congee variants, traditional preparations incorporated multiple grains, legumes, and seeds, providing a broader micronutrient profile than monoculture rice
• Fermentation in traditional food systems — fermented foods (natto, miso, kimchi, sauerkraut, kefir) contain microbial thiamine synthesis byproducts; while quantitatively minor, they contribute to traditional dietary adequacy

Historical lessons for modern clinical practice:

• The Eijkman-Funk-Jansen-Williams arc (see Pro Guide §13 history summary in Consumer view, or reference [46]Lonsdale review — biochemistry & history. Open Source ↗ [41]Tylicki 2018 — synthesis history. Open Source ↗ for detail) demonstrates how a public-health intervention can succeed empirically (Takaki 1880s, US flour enrichment 1942) before the underlying biochemistry is understood
• Modern populations remain at risk when staple-food fortification is interrupted: the 1980s WIC infant-formula outbreak in the US (formulator omitted thiamine) and the 2003 Israeli infant formula outbreak both produced acute infantile beriberi in industrialized settings
• The 'traditional vs scientific medicine' divide that hampered the Japanese Army's response to beriberi is a recurring cautionary tale about dismissing empirical clinical evidence without mechanistic explanation

14. Quality Control

Compendial monographs. Thiamine hydrochloride and thiamine mononitrate are monographed in the major pharmacopoeias with harmonized identification, assay, and impurity limits:

Assay methodology. USP General Chapter <531> (Thiamine Assay) describes the official method [40]USP <531> revision notice. Open Source ↗. Historical procedure used thiochrome fluorometric quantification (oxidation of thiamine with ferricyanide to thiochrome; fluorescence at 444 nm with excitation at 365 nm). The 2017 USP <531> revision harmonized the official method to HPLC with fluorescence detection, providing improved selectivity in complex matrices [40]USP <531> revision notice. Open Source ↗.

Impurity and degradation product limits per USP monograph:

Stability profile.

Industrial manufacturing. Industrial thiamine synthesis is predominantly via the Williams-Cline route (1936, Merck commercial process [41]Tylicki 2018 — synthesis history. Open Source ↗) or the Grewe-Hill route, both ultimately combining a substituted pyrimidine moiety with a substituted thiazole moiety through nucleophilic substitution. The original Merck process was a challenging 15-step synthesis. Modern commercial production is concentrated in a small number of large-scale facilities, primarily in China and a few European producers. Annual global production capacity exceeds 10,000 metric tons, supporting pharmaceutical, food-fortification, supplement, and animal-feed markets.

Dietary-supplement quality verification. Voluntary third-party certification programs provide independent assurance beyond regulatory cGMP requirements:

Regulatory cGMP for dietary supplements is MANDATORY under 21 CFR 111 for all US dietary supplements, but enforcement and quality variation exist between manufacturers. Third-party verification provides additional independent assurance.

Counterfeit and substandard product detection:

• FDA enforcement actions and import alerts available at fda.gov for specific manufacturers and products of concern
• USP Verified seal is the highest practical assurance for label-claim accuracy
• Pricing far below market median is a red flag for substandard product
• Lack of clear US-based manufacturer contact information is a red flag
• Loss of potency over time is expected — products near expiry may have ≥10% loss from labeled potency